A Risk-Benefit Assessment of Moclobemide in the Treatment of Depressive Disorders
- 1 January 1995
- journal article
- review article
- Published by Springer Nature in Drug Safety
- Vol. 12 (1) , 46-54
- https://doi.org/10.2165/00002018-199512010-00004
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdosesThe Lancet, 1993
- Serotonin syndrome caused by a moclobemide-clomipramine interaction.BMJ, 1993
- An update of recent moclobemide interaction dataInternational Clinical Psychopharmacology, 1993
- The role of moclobemide in endogenous depressionInternational Clinical Psychopharmacology, 1993
- Moclobemide — Placebo-controlled trialsInternational Clinical Psychopharmacology, 1993
- RIMA — A new concept in the treatment of depression with moclobemideInternational Clinical Psychopharmacology, 1993
- A Placebo-controlled Study of the Antidepressant Activity of Moclobemide,A New MAO-A InhibitorPharmacopsychiatry, 1984
- Selective inhibitors of monoamine oxidase A and B: Biochemical, pharmacological, and clinical propertiesMedicinal Research Reviews, 1984
- Hypertensive Interactions Between Monoamine Oxidase Inhibitors and FoodstuffsThe British Journal of Psychiatry, 1967
- Clinical Trial of the Treatment of Depressive IllnessBMJ, 1965